{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:45:42Z","timestamp":1785897942226,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["30915"],"award-info":[{"award-number":["30915"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejca.2026.116867","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:21:00Z","timestamp":1780676460000},"page":"116867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7461-023X","authenticated-orcid":false,"given":"Marco","family":"Tagliamento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-4542","authenticated-orcid":false,"given":"Marco","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-4579","authenticated-orcid":false,"given":"Eva","family":"Blondeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-6109","authenticated-orcid":false,"given":"Filippo","family":"Dall\u2019Olio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-051X","authenticated-orcid":false,"given":"Mihaela","family":"Aldea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-8582","authenticated-orcid":false,"given":"Carlo","family":"Genova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3966-1984","authenticated-orcid":false,"given":"Arianna","family":"Marinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1565-8310","authenticated-orcid":false,"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116867_bib1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2026.116867_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK -positive non\u2013small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116867_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116867_bib4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100527","article-title":"Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-na\u00efve Japanese patients with ALK-positive non-small-cell lung cancer","volume":"7","author":"Hotta","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116867_bib6","article-title":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study","author":"Peters","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib7","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK -positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116867_bib8","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK -positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116867_bib9","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase\u2212positive non\u2013small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.lungcan.2022.01.006","article-title":"ALK fusion variant 3a\/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061)","volume":"165","author":"Li","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116867_bib11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2024.07.009","article-title":"Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: real-world outcomes from the GuardantINFORM database","volume":"19","author":"Parikh","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib12","series-title":"Biology and Management of Multiple Myeloma","first-page":"127","article-title":"Tumor Burden","author":"Joshua","year":"2004"},{"key":"10.1016\/j.ejca.2026.116867_bib13","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1016\/j.jtho.2021.01.919","article-title":"P52.06 \u201chigh tumor burden\u201d in metastatic non-small cell lung cancer: defining the concept","volume":"16","author":"Higuera","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e21061","article-title":"Trying to define \u201chigh tumor burden\u201d in non-small cell lung cancer: a delphi survey","volume":"40","author":"Mielgo-Rubio","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.116867_bib15","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jtho.2019.05.031","article-title":"Body mass index (BMI), BMI change, and overall survival in patients with SCLC and NSCLC: a pooled analysis of the international lung cancer consortium","volume":"14","author":"Shepshelovich","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.14740\/wjon1244","article-title":"Low body mass index is an independent prognostic factor in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitor","volume":"10","author":"Minami","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib17","doi-asserted-by":"crossref","first-page":"ii49","DOI":"10.1093\/annonc\/mdz063.025","article-title":"Obesity has an impact on the efficacy of EGFR-TKI in NSCLC patients harbouring EGFR mutation: a real-world study","volume":"30","author":"Ding","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib18","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.3390\/cancers15133422","article-title":"Evaluation of Efficacy of ALK inhibitors according to body mass index in ALK rearranged NSCLC patients\u2014a retrospective observational study","volume":"15","author":"Siringo","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116867_bib19","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.116867_bib20","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M","article-title":"A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data","volume":"19","author":"Bonetti","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2026.116867_bib21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/sim.3524","article-title":"A small sample study of the STEPP approach to assessing treatment\u2013covariate interactions in survival data","volume":"28","author":"Bonetti","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2026.116867_bib22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/1740774516643297","article-title":"Subpopulation TReatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes","volume":"13","author":"Yip","year":"2016","journal-title":"Clin Trials"},{"key":"10.1016\/j.ejca.2026.116867_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.e19041","article-title":"The effect of body mass index (BMI) on non-small cell lung cancer (NSCLC) mortality","volume":"32","author":"Abu Hejleh","year":"2014","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.116867_bib24","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3390\/diagnostics11122170","article-title":"Prognostic Markers of survival among japanese patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving first-line alectinib","volume":"11","author":"Takeda","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejca.2026.116867_bib25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO-24-01579","article-title":"Body weight gain associated with alectinib in patients With ALK+ non\u2013small cell lung cancer: pooled analysis of individual patient data from four prospective clinical trials","volume":"43","author":"Sikkema","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.116867_bib26","article-title":"Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment","volume":"10","author":"Yadav","year":"2024","journal-title":"Eur J Med Chem Rep"},{"key":"10.1016\/j.ejca.2026.116867_bib27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2019.10.014","article-title":"Efficacy of platinum\/pemetrexed combination chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors","volume":"15","author":"Lin","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib28","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1186\/s12885-023-11417-w","volume":"23","author":"Wakuda","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.116867_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101191","article-title":"Will the clinical development of 4th-generation \u201cdouble mutant active\u201d ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?","volume":"14","author":"Ou","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8666","article-title":"Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study","volume":"43","author":"Popat","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.116867_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e20621","article-title":"Impact of tumor burden on outcomes after immune versus conventional therapies","volume":"43","author":"Gowda","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.116867_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.03.020","article-title":"Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non\u2013small cell lung cancer treated with first-line pembrolizumab","volume":"150","author":"Dall\u2019Olio","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116867_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8611","article-title":"Effect of tumor burden on survival in patients with stage IV EGFR -mutant NSCLC receiving osimertinib monotherapy","volume":"42","author":"Delasos","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.116867_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00884","article-title":"Evaluating tumor burden as a predictive biomarker for epidermal growth factor receptor targeted kinase inhibitor therapy in advanced non\u2013small cell lung cancer","volume":"10","author":"Terashima","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib35","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1002\/cncr.33118","article-title":"Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116867_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2020.12.011","article-title":"Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC","volume":"16","author":"Lam","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116867_bib37","doi-asserted-by":"crossref","first-page":"8191","DOI":"10.2147\/CMAR.S213572","article-title":"Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib","volume":"11","author":"Liang","year":"2019","journal-title":"CMAR"},{"key":"10.1016\/j.ejca.2026.116867_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00109-020-01874-2","article-title":"Clinical implications of intratumor heterogeneity: challenges and opportunities","volume":"98","author":"Ram\u00f3n Y Cajal","year":"2020","journal-title":"J Mol Med"},{"key":"10.1016\/j.ejca.2026.116867_bib39","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","article-title":"Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial","volume":"18","author":"Yang","year":"2023","journal-title":"J Thorac Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:58:47Z","timestamp":1785895127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S0959804926006489"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116867","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116867"}}